Voyager Therapeutics (VYGR) CMO resigns as CEO assumes interim clinical role

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. announced that Chief Medical Officer Toby Ferguson, M.D., Ph.D. has decided to resign from his role and all other positions with the company and its subsidiaries, effective February 20, 2026, to pursue a new opportunity.

The company states that Dr. Ferguson’s resignation is not due to any disagreement with Voyager. President and Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D. has agreed to assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis after the resignation becomes effective.

Insights

Biopharma governance and R&D strategy analyst

Voyager reports CMO exit with CEO covering clinical leadership on an interim basis.

Voyager Therapeutics discloses that its Chief Medical Officer, Toby Ferguson, M.D., Ph.D., will resign effective February 20, 2026 to pursue a new opportunity. The company explicitly notes that his departure is not the result of any disagreement with Voyager.

Clinical leadership will transition temporarily to President and CEO Alfred W. Sandrock, Jr., M.D., Ph.D., who will take on key responsibilities, including strategic guidance for clinical development programs, on an interim basis. This helps maintain continuity in oversight of clinical activities while a longer-term structure is determined.

The filing does not detail succession plans, timelines, or potential organizational changes beyond the interim arrangement. Subsequent company communications or filings may clarify permanent leadership for clinical development and any impact on program execution.

false 0001640266 0001640266 2026-02-09 2026-02-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 9, 2026

Voyager Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37625		46-3003182
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

75 Hayden Avenue Lexington, Massachusetts		02421
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (857) 259-5340

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	VYGR	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Chief Medical Officer

On February 9, 2026, Toby Ferguson, M.D., Ph.D. notified Voyager Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Medical Officer of the Company and from any and all other positions he holds with the Company and any of its subsidiaries, effective February 20, 2026, to pursue a new opportunity. Dr. Ferguson’s resignation is not a result of any disagreement with the Company.

Item 8.01 Other Events. 

Alfred W. Sandrock, Jr., M.D., Ph.D., the Company’s current President and Chief Executive Officer, has agreed to assume key responsibilities, including strategic guidance for the Company’s clinical development programs, on an interim basis following the effective date of Dr. Ferguson’s resignation.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 12, 2026	VOYAGER THERAPEUTICS, INC.
	By:	/s/ Alfred W. Sandrock, Jr., M.D., Ph.D.
		Alfred W. Sandrock, Jr., M.D., Ph.D.
		Chief Executive Officer, President, and Director
		(Principal Executive Officer)

3

FAQ

What leadership change did Voyager Therapeutics (VYGR) disclose in this 8-K?

Voyager Therapeutics disclosed that Chief Medical Officer Toby Ferguson, M.D., Ph.D., will resign effective February 20, 2026. He is leaving to pursue a new opportunity, and his departure covers all positions with the company and its subsidiaries.

Did Voyager Therapeutics (VYGR) report any disagreement related to the CMO’s resignation?

The company stated that Dr. Toby Ferguson’s resignation is not the result of any disagreement with Voyager Therapeutics. This language is commonly used to indicate that there were no reported disputes over operations, policies, or practices prompting the departure.

Who will assume clinical leadership after Voyager Therapeutics’ CMO resigns?

Voyager Therapeutics’ President and Chief Executive Officer, Alfred W. Sandrock, Jr., M.D., Ph.D., has agreed to assume key responsibilities on an interim basis. These responsibilities include providing strategic guidance for the company’s clinical development programs following the effective date of Dr. Ferguson’s resignation.

When does the Voyager Therapeutics (VYGR) CMO resignation become effective?

The resignation of Chief Medical Officer Toby Ferguson, M.D., Ph.D., becomes effective on February 20, 2026. He notified Voyager Therapeutics of his decision on February 9, 2026, providing a short transition period before his departure takes effect.

Does the Voyager Therapeutics 8-K describe changes to other executive roles?

The 8-K describes that Alfred W. Sandrock, Jr., M.D., Ph.D., currently President and Chief Executive Officer, will take on additional interim responsibilities. It does not announce changes to his existing titles; instead, it expands his duties to cover key clinical leadership functions.

What positions is Toby Ferguson leaving at Voyager Therapeutics (VYGR)?

Toby Ferguson, M.D., Ph.D., is resigning from his position as Chief Medical Officer of Voyager Therapeutics and from any and all other positions he holds with the company and its subsidiaries. The filing does not list each additional role individually.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.9 KB